Next Article in Journal
Comment on van den Hurk et al. The Emergence of Japanese Encephalitis Virus in Australia in 2022: Existing Knowledge of Mosquito Vectors. Viruses 2022, 14, 1208
Next Article in Special Issue
Insights into the Molecular Epidemiology of Foot-and-Mouth Disease Virus in Russia, Kazakhstan, and Mongolia in Terms of O/ME-SA/Ind-2001e Sublineage Expansion
Previous Article in Journal
Simple Wastewater Preparation Protocol Applied to Monitor the Emergence of the Omicron 21L/BA.2 Variant by Genome Sequencing
Previous Article in Special Issue
Establishing an In Vitro System to Assess How Specific Antibodies Drive the Evolution of Foot-and-Mouth Disease Virus
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: King et al. Establishing an In Vitro System to Assess How Specific Antibodies Drive the Evolution of Foot-and-Mouth Disease Virus. Viruses 2022, 14, 1820

1
The Pirbright Institute, Woking GU24 0NF, UK
2
Department of Microbial and Cellular Sciences, Faculty of Health and Medical Sciences, School of Biosciences and Medicine, University of Surrey, Guildford GU2 7XH, UK
3
Defence Science and Technology Laboratory (DSTL), Chemical, Biological and Radiological Division, Porton Down, Salisbury SP4 0JQ, UK
*
Author to whom correspondence should be addressed.
Viruses 2023, 15(2), 269; https://doi.org/10.3390/v15020269
Submission received: 26 October 2022 / Accepted: 29 December 2022 / Published: 18 January 2023
(This article belongs to the Special Issue Global Foot-and-Mouth Disease Control)

1. Missing Figure

In the original publication [1], Figure 4 and the corresponding legend were missing. The added Figure 4, showing surface-exposed non-synonymous mutations, appears below. The figure was not included in the original manuscript by mistake, for which the authors would like to apologise.

2. Text Correction

There was an error in the original publication. In the Results, Section 3.4, Paragraph 2, sentence “These were located at VP266, VP280 and VP1155” should refer to Figure 4. In the Discussion, Paragraph 8, VP34 should say VP34.
Corrections have been made to Results, Non-Synonymous Substitutions Exposed on the FMDV Capsid Surface, Paragraph 2, and Discussion, Paragraph 8. Corrected paragraphs appear below.

2.1. Results, Section 3.4, Paragraph 2

From the six non-synonymous mutations detected in the region encoding the capsid proteins and described above, three were exposed on the surface of the viral capsid. These were located at VP266, VP280, and VP1155 (Figure 4). For VP266, substitution from leucine (L) to phenylalanine (F) led to an accommodation of a larger aromatic side chain, while keeping the site’s hydrophobic properties. Amino acid substitution from lysine (K) to glutamic acid (E) at position VP280 led to a change in the positively charged side chain to a negatively charged side chain. The substitution of alanine (A) to threonine (T) at position VP1155 led to a change from a hydrophobic side chain to a polar, uncharged side chain. In both latter cases, the change in the side chain length was only of a single carbon.

2.2. Discussion, Section 4, Paragraph 8

In addition to surface-exposed amino acid substitutions, there were three amino acid mutations (L71P in VP4, P4S in VP3, and Q58H in VP1) that were specific to the treatment with the FMDV sub-neutralising sera but found at locations on the surface of the capsid at which they were not predicted to appear. Two of these (at locations VP471 and VP34) were found in the viral population grown in the presence of Challenge Serum 4942, the viral population which showed a reversion in anti-sera-induced delay in the occurrence of CPE through a potential immune escape substitution at VP1155. While the N-terminus of the VP4 protein in other picornaviruses is known to be transiently exposed to the outside of the capsid during a process called virus breathing [48,49,50], it is not clear whether the C-terminus of the VP4 protein is exposed to the antibodies. Finally, a single synonymous substitution (S37) was found in the region encoding the VP2 protein. While this substitution was present at a low frequency in the starting inoculum and in samples treated with Control sera, it rose in frequency, reaching the consensus in the viral population passaged in the presence of Field Serum 3159, the viral population which showed a reversion of the delay in time to CPE. Further studies are required to verify the phenotype of these mutations.
The authors state that the scientific conclusions are unaffected. These corrections were approved by the Academic Editor. The original publication has also been updated.

Reference

  1. King, D.J.; Freimanis, G.; Neil, C.; Shaw, A.; Tuthill, T.J.; Laing, E.; King, D.P.; Lasecka-Dykes, L. Establishing an In Vitro System to Assess How Specific Antibodies Drive the Evolution of Foot-and-Mouth Disease Virus. Viruses 2022, 14, 1820. [Google Scholar] [CrossRef] [PubMed]
Figure 4. Surface-exposed non-synonymous mutations. The mutations that became fixed at consensus level in the viral populations passaged in the presence of sera from the Field and Challenge groups (but not identified within the starting inoculum or viruses passaged in the presence of the Control sera) were mapped onto the crystal structure of recombinant FMDV A22-H2093F empty capsid. Surface representation of the FMDV capsid (A). Individual pentamers enlarged to show mutations identified in the viral population passaged in the presence of Field Serum 3817, Field Serum 3159, and Challenge Serum 4942, respectively (BD). The VP2, VP3, and VP1 proteins are highlighted in green, pink, and blue, respectively. Mutations are shown in red.
Figure 4. Surface-exposed non-synonymous mutations. The mutations that became fixed at consensus level in the viral populations passaged in the presence of sera from the Field and Challenge groups (but not identified within the starting inoculum or viruses passaged in the presence of the Control sera) were mapped onto the crystal structure of recombinant FMDV A22-H2093F empty capsid. Surface representation of the FMDV capsid (A). Individual pentamers enlarged to show mutations identified in the viral population passaged in the presence of Field Serum 3817, Field Serum 3159, and Challenge Serum 4942, respectively (BD). The VP2, VP3, and VP1 proteins are highlighted in green, pink, and blue, respectively. Mutations are shown in red.
Viruses 15 00269 g001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

King, D.J.; Freimanis, G.; Neil, C.; Shaw, A.; Tuthill, T.J.; Laing, E.; King, D.P.; Lasecka-Dykes, L. Correction: King et al. Establishing an In Vitro System to Assess How Specific Antibodies Drive the Evolution of Foot-and-Mouth Disease Virus. Viruses 2022, 14, 1820. Viruses 2023, 15, 269. https://doi.org/10.3390/v15020269

AMA Style

King DJ, Freimanis G, Neil C, Shaw A, Tuthill TJ, Laing E, King DP, Lasecka-Dykes L. Correction: King et al. Establishing an In Vitro System to Assess How Specific Antibodies Drive the Evolution of Foot-and-Mouth Disease Virus. Viruses 2022, 14, 1820. Viruses. 2023; 15(2):269. https://doi.org/10.3390/v15020269

Chicago/Turabian Style

King, David J., Graham Freimanis, Chris Neil, Andrew Shaw, Tobias J. Tuthill, Emma Laing, Donald P. King, and Lidia Lasecka-Dykes. 2023. "Correction: King et al. Establishing an In Vitro System to Assess How Specific Antibodies Drive the Evolution of Foot-and-Mouth Disease Virus. Viruses 2022, 14, 1820" Viruses 15, no. 2: 269. https://doi.org/10.3390/v15020269

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop